Caixin
Dec 08, 2021 03:47 AM
BUSINESS

Fosun and BioNTech Explore Joint Developing Omicron-Specific Vaccine

As of Nov. 27, 13.5 million doses of the Comirnaty mRNA vaccine were administered in Hong Kong, Macao and Taiwan.
As of Nov. 27, 13.5 million doses of the Comirnaty mRNA vaccine were administered in Hong Kong, Macao and Taiwan.

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (600196.SH) said it will actively work with its German partner BioNTech SE to develop a new vaccine targeting the omicron variant of Covid-19, and it may take three to four months to win regulatory approval.

Fosun is the exclusive partner of BioNTech for marketing the mRNA vaccine co-developed by BioNTech and U.S. drug giant Pfizer Inc. in Greater China, including Hong Kong, Macao and Taiwan. Known in China as the Comirnaty vaccine, the product hasn’t been approved for the Chinese mainland.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code